SSY Group Limited

Equities

2005

KYG8406X1034

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:16 2024-04-24 am EDT 5-day change 1st Jan Change
4.76 HKD +1.49% Intraday chart for SSY Group Limited +3.48% -3.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator MT
SSY Group Logs Nearly 15% Boost in Q1 Profit MT
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs MT
SSY Group Limited Announces Update on Product Development CI
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration MT
SSY Group Limited Provides Update on Product Development CI
SSY Group's Profit Jumps 17% in 2023 MT
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SSY Group Obtains Drug Administration Approval for Diabetes Drug MT
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator MT
SSY Group Limited Announces Update on Product Development CI
SSY Group Gets Bulk Drug Approval from Chinese Authorities MT
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market CI
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation MT
SSY Group Limited Receives Approval for Gliclazide Tablet CI
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection MT
SSY Group Limited Provides Update on Product Development CI
SSY Group’s Anesthetic Drug Granted Production, Registration Approval in China MT
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China CI
SSY Group Gets Bulk Drug Approval in China MT
SSY Group Limited Announces Update on Product Development CI
SSY Obtains Chinese Bulk Drug Registration Nod for Lidocaine Hydrochloride MT
Chart SSY Group Limited
More charts
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.76 HKD
Average target price
6.227 HKD
Spread / Average Target
+30.81%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2005 Stock
  4. News SSY Group Limited
  5. SSY : Wins Regulatory Go-Ahead for Production, Registration of Epilepsy Treatment in China; Shares Drop 4%